SCA
CRL icon

SAC Capital Advisors’s Charles River Laboratories CRL Stock Holding History

SAC Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-125,000
Closed -$5.13M – 1799
2013
Q2 		$5.13M Buy
+125,000
New +$5.36M 0.03% 525

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

SAC Capital Advisors's CRL Position: Q1 2014 in Review

SAC Capital Advisors sold out of Charles River Laboratories (CRL) in Q1 2014, closing a stake of 38,698 shares — an estimated $2.05M sold.

SAC Capital Advisors first reported a position in CRL in Q2 2013 and held it in 3 quarters. The position peaked at $2.05M in Q4 2013. 258 funds tracked by Wall St. Rank hold CRL as of Q1 2014.

  • SAC Capital Advisors reported no remaining Charles River Laboratories position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 38,698 Charles River Laboratories shares in Q1 2014, an estimated $2.05M.
  • SAC Capital Advisors first reported a position in Charles River Laboratories in Q2 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Charles River Laboratories position peaked at $2.05M in Q4 2013.
  • 258 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.